Maxim Group Starts Cardio3 BioSciences SA (CIBSF) at Buy

Maxim Group initiates coverage on Cardio3 BioSciences SA (OTC: CIBSF) (CARD.BR) with a Buy rating and EUR 61 price target.

Analyst Jason McCarthy commented, "With pivotal programs in autologous cardiopoietic stem cell heart therapy underway in Europe and one about to begin in the US, combined with early stage CAR-T programs (phase I is underway), we are excited about the prospects in both regenerative medicine and immuno-oncology spaces."

He added, "The CAR-T program is differentiated and targets a broad base of cancers; its not another CD19 approach and the platform has the potential to develop allogeneic CAR-T products."

For an analyst ratings summary and ratings history on Cardio3 BioSciences SA click here. For more ratings news on Cardio3 BioSciences SA click here.

Shares of Cardio3 BioSciences SA closed at $56.88 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS